Migraine drug AJOVY under Real-World safety spotlight
NCT ID NCT05342493
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks about 1,000 people with migraine who are taking AJOVY (fremanezumab) as part of their regular care. The goal is to see how safe the drug is over the long term, especially regarding heart problems. Researchers will also collect information on how well it works. The study does not assign treatment—it simply observes what happens in everyday use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fremanezumab (AJOVY)
What this could lead to
If successful, this study could confirm that AJOVY is safe for long-term use and help doctors better manage migraine treatment.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may show unexpected side effects or no clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pharmacovigilance Department
RECRUITINGOsaka, 540-0021, Japan
Contact